Abstract
Background: Multiple sclerosis (MS) is one of the most widespread chronic neurological diseases that manifests itself by progressive demyelination in the central nervous system. The study of MS pathogenesis begins with the onset of the relapsing–remitting phase of the disease, which becomes apparent due to microglia activation, neuroinflammation and demyelination/ remyelination in the white matter. The following progressive phase is accompanied by severe neurological symptoms when demyelination and neurodegeneration are spread to both gray and white matter. In this review, we discuss a possible role of mitochondrial reactive oxygen species (mtROS) in MS pathogenesis, mechanisms of mtROS generation and effects of some mitochondria-targeted antioxidants as potential components of MS therapy.
Results: In the early phase of MS, mtROS stimulate NLRP3 inflammasomes, which is critical for the formation of local inflammatory lesions. Later, mtROS contribute to blood-brain barrier disruption induced by mediators of inflammation, followed by infiltration of leukocytes. ROS generated by leukocytes and activated microglia promote mitochondrial dysfunction and oligodendrocyte cell death. In the progressive phase, neurodegeneration also depends on excessive mtROS generation. Currently, only a few immunomodulatory drugs are approved for treatment of MS. These drugs mainly reduce the number of relapses but do not stop MS progression. Certain dietary and synthetic antioxidants have demonstrated encouraging results in animal models of MS but were ineffective in the completed clinical trials. Conclusion: Novel mitochondria-targeted antioxidants could be promising components of combined programs for MS therapy considering that they can be applied at extremely low doses and concurrently demonstrate anti-inflammatory and neuroprotective activities.Keywords: Multiple sclerosis, oligodendrocytes, demyelination, inflammasome, mitochondria, reactive oxygen species, mitochondria-targeted antioxidants, neuroprotection.
Current Medicinal Chemistry
Title:Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis
Volume: 24 Issue: 19
Author(s): Elena Fetisova, Boris Chernyak*, Galina Korshunova, Maria Muntyan*Vladimir Skulachev
Affiliation:
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow,Russian Federation
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow,Russian Federation
Keywords: Multiple sclerosis, oligodendrocytes, demyelination, inflammasome, mitochondria, reactive oxygen species, mitochondria-targeted antioxidants, neuroprotection.
Abstract: Background: Multiple sclerosis (MS) is one of the most widespread chronic neurological diseases that manifests itself by progressive demyelination in the central nervous system. The study of MS pathogenesis begins with the onset of the relapsing–remitting phase of the disease, which becomes apparent due to microglia activation, neuroinflammation and demyelination/ remyelination in the white matter. The following progressive phase is accompanied by severe neurological symptoms when demyelination and neurodegeneration are spread to both gray and white matter. In this review, we discuss a possible role of mitochondrial reactive oxygen species (mtROS) in MS pathogenesis, mechanisms of mtROS generation and effects of some mitochondria-targeted antioxidants as potential components of MS therapy.
Results: In the early phase of MS, mtROS stimulate NLRP3 inflammasomes, which is critical for the formation of local inflammatory lesions. Later, mtROS contribute to blood-brain barrier disruption induced by mediators of inflammation, followed by infiltration of leukocytes. ROS generated by leukocytes and activated microglia promote mitochondrial dysfunction and oligodendrocyte cell death. In the progressive phase, neurodegeneration also depends on excessive mtROS generation. Currently, only a few immunomodulatory drugs are approved for treatment of MS. These drugs mainly reduce the number of relapses but do not stop MS progression. Certain dietary and synthetic antioxidants have demonstrated encouraging results in animal models of MS but were ineffective in the completed clinical trials. Conclusion: Novel mitochondria-targeted antioxidants could be promising components of combined programs for MS therapy considering that they can be applied at extremely low doses and concurrently demonstrate anti-inflammatory and neuroprotective activities.Export Options
About this article
Cite this article as:
Fetisova Elena, Chernyak Boris *, Korshunova Galina , Muntyan Maria*, Skulachev Vladimir, Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170316114452
DOI https://dx.doi.org/10.2174/0929867324666170316114452 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin Expression in Alzheimer's Brain
Current Alzheimer Research An Overview of Highly Optically Pure Chloramphenicol Bases: Applications and Modifications
Mini-Reviews in Medicinal Chemistry Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Understanding Genetic Factors in Idiopathic Scoliosis, a Complex Disease of Childhood
Current Genomics Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Aquaporin 4 in Astrocytes is a Target for Therapy in Alzheimer's Disease
Current Pharmaceutical Design High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews Editorial (Hot Topic: Mitochondrion: An Organelle More and More Implication in New Processes)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Fluorescent Anti-Cancer Agent, 3,6-bis(1-methyl-4-vinylpyridinium) Carbazole Diiodide, Stains G-Quadruplexes in Cells and Inhibits Tumor Growth
Current Topics in Medicinal Chemistry Synthesis of piperidine-4-one Derivative Containing Dipeptide: An Acetyl cholinesterase and β-secretase Inhibitor
Anti-Infective Agents Altering Outcomes in Juvenile Offending: The Evidence Base
Adolescent Psychiatry The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Current Alzheimer Research Allosteric Modulators of Class B G-Protein-Coupled Receptors
Current Neuropharmacology MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Immunotherapy of Melanoma
Current Molecular Pharmacology Clozapine Safety, 40 Years Later
Current Drug Safety Gang Involvement, Mental Health Difficulties and Exposure to Violence in 11-16-Year-Old School Students
Adolescent Psychiatry Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Molecular Characterization of the Hetero-Assembly of β-Amyloid Peptide with Islet Amyloid Polypeptide
Current Pharmaceutical Design